大象传媒

San D脿mhair 2023 chaidh an druga Wegovy a cheadachadh ann an Alba. Tha Semaglutide ri lorg anns an druga, a tha cuideachd ri lorg san leighis do thinneas an t-si霉cair, Ozempic. Tha Semaglutide a' m霉chadh c脿il-b矛dh agus tha m貌ran air a bhith ga moladh airson cho 猫ifeachdach 's a tha i airson call cuideam. Air a d猫anamh san Danmhairg, tha iarrtas air s矛or 猫irigh sna beagan bhliadhnaichean a dh'fhalbh. Tha seo air Novo Nordisk, a' chompanaidh air a c霉laibh, fh脿gail mar a' chompanaidh as luachmhoire san Roinn 贰貌谤辫补, agus an luach aca nas 脿irde na GDP na Danmhairg. Ach tha rabhaidhean air a bhith ann gu bheil iarrtas cho m貌r a' f脿gail iadsan a tha feumach air Semaglutide, leithid daoine le tinneas an t-si霉cair agus iadsan a tha f矛or throm, 脿s aonais cothrom oirre. Air 贰貌谤辫补 na seachdain sa tha Anndra MacFhionghain ag aithris air soirbheachas na druga, agus a' faighneachd d猫 bhios seo a' ciallachadh do mhuinntir na h-Alba, agus i a-nis ri fhaighinn an seo.

In October 2023 Wegovy was made available on prescription in Scotland. This drug contains the active ingredient Semaglutide, also found in the diabetes drug Ozempic. Semaglutide suppresses the appetite and has been hailed by many as a 'miracle-drug' for weight-loss. Produced in Denmark, demand has sky-rocketted in recent years and has made its maker, Novo Nordisk, the most valuable company in Europe, its worth surpassing the whole GDP of Denmark. But there have been warnings that such high demand is leaving those who really need Semaglutide, such as diabetics and the morbidly obese, without access. On this week's 贰貌谤辫补 Andrew MacKinnon reports on the recent success of the drug, and asks what it means for people in Scotland, now that it has been made available here.